TL;DR — The American Rhinologic Society runs three meetings in 2026: ARS at COSM 2026 in Phoenix April 25-26, the Summer Sinus Symposium in Miami Beach July 24-26, and the 72nd Annual Meeting in Los Angeles October 15-17 — back-to-back with AAO-HNSF October 17-20 at the LA Convention Center. ARS is the most concentrated rhinology, sinus, and endoscopic skull base audience in the United States — small, surgical, and evidence-driven. All-in cost for a credible 10x10 presence at the LA annual meeting runs $15,000-$30,000; a sponsored symposium with a hands-on cadaver lab across the full ARS calendar can clear $100,000. Win the year by pairing ARS-aligned clinical evidence, fellowship-targeted education, and a combined ARS + AAO-HNSF travel plan in LA in October.

What ARS Is — and Why 2026 Is a High-Leverage Year

The American Rhinologic Society (ARS) is the professional home of rhinologists, endoscopic sinus and skull base surgeons, and the otolaryngologists who treat the highest-acuity nasal and paranasal sinus disease. Membership is small by design and the meetings are deeply clinical. There is no other U.S. venue where the concentration of rhinology decision-makers — surgeons making product, capital, and biologic-referral decisions for chronic rhinosinusitis with nasal polyps, balloon sinus dilation, image-guided navigation, sinus stents, and endoscopic skull base instrumentation — is this high.

ARS runs three meetings in 2026. ARS at COSM 2026 is held alongside the Combined Otolaryngology Spring Meetings on April 25-26 at the Phoenix Convention Center; this is a science-dense spring touchpoint that draws academic rhinologists and fellowship faculty. The 2026 Summer Sinus Symposium runs July 24-26 at the Loews Miami Beach Hotel — a smaller, hands-on, education-led summer meeting that is unusually high-leverage for vendors offering surgical training, simulators, or cadaver labs. The 72nd Annual Meeting of the ARS runs October 15-17 in Los Angeles, immediately preceding the AAO-HNSF Annual Meeting & OTO EXPO at the Los Angeles Convention Center on October 17-20. The 2026 calendar collapses two of the highest-yield ENT shows of the year into a single Los Angeles week, and the device vendors who plan for both as a single program — not two disconnected exhibits — finish the year with the strongest fall pipeline.

The audience is small but extraordinarily concentrated. Roughly 600-900 active rhinologists practice in the United States, and a meaningful share attend at least one ARS meeting each year. Add fellowship-trained skull base surgeons, fellows, advanced practice providers, allergists co-managing chronic rhinosinusitis, and a cohort of general otolaryngologists with high sinus volume, and you get an ARS floor that is essentially impossible to replicate at any other U.S. meeting. For vendors selling endoscopic sinus surgery, image guidance, sinus implants, biologics for CRSwNP, or endoscopic skull base instrumentation, ARS is where the year's deals start.

ARS 2026: The Three Meetings You Need on the Calendar

The cost-per-attendee math at ARS looks expensive next to broad ENT meetings like AAO-HNSF. The cost-per-qualified-rhinology-decision-maker math is the opposite. A 10x10 at the LA annual meeting that puts your team in front of 100-200 active rhinologists across three days, with 10-15 scheduled meetings with named target accounts, is typically the most efficient sinus-and-skull-base pipeline event of the year. The trick is exhibiting like the rhinology audience is small and high-value, and treating COSM and Summer Sinus as relationship-building investments that compound into LA in October.

Pre-Conference Strategy: Build a Rhinologist-Level Target List

ARS is small enough that meaningful floor time is almost entirely pre-booked. Rhinologists do not wander aimlessly — they have specific panels to attend, specific colleagues to find, and specific vendors they have decided to evaluate. If your team plans to "see who shows up," you will leave LA with badge scans and no pipeline. Pre-show outreach is not optional at ARS.

Build a target rhinologist list by mid-August for the October annual meeting. Start with every fellowship-trained rhinologist and high-volume endoscopic sinus surgery program you have ever sold into, then layer in the top 100-150 hospital-based and academic rhinology and skull base divisions in your geography. Prioritize ARS-aligned fellowship programs (fellows place adoption seeds that flower three to five years later), high-volume balloon sinus dilation programs, and academic centers with strong endoscopic skull base practices. Aim for a named target list of 80-150 rhinologists with the specific clinical, biologic, and capital decisions each one is making in the next 12 months.

Run a five-touch outreach sequence starting eight weeks out. The cadence that consistently books meetings at specialty meetings: a personalized email referencing a recent IFAR or Otolaryngology-HNS publication, a LinkedIn connection request from a clinical specialist (not a sales rep), a value-led second email with a peer-reviewed reference or surgical-video link, a third email offering a specific LA meeting slot, and a final pre-show confirmation. Our pre-conference email campaigns guide walks through subject-line patterns, timing, and templates that translate cleanly to ARS.

Leverage ARS-aligned channels. Rhinologists read a small, well-defined set of journals — the International Forum of Allergy & Rhinology and Otolaryngology-Head and Neck Surgery dominate the clinical reading list — follow a small circle of fellowship-program faculty on social, and pay close attention to ARS-sponsored education and webinars. Pre-show advertising and content placement inside that ecosystem reaches the rhinology audience at a fraction of the cost of general ENT media, with much higher clinical credibility. If you sell into rhinology and you are not present in ARS-aligned media in the eight weeks before LA, you are leaving meeting yield on the table.

Booth Design and Messaging for Rhinologists and Skull Base Surgeons

ARS attendees are subspecialty-trained surgeons who can read your data closely and will publicly correct overreach. Booth design and messaging built for a broad ENT or primary-care ENT audience will be politely dismissed at ARS. Win the floor by treating the audience as the clinical experts they are.

Build the booth around three zones. Surgical video zone: looped, high-quality endoscopic footage of your device or procedure in the hands of a credible ARS-aligned surgeon, with case selection criteria and complication rates honestly displayed. Evidence zone: peer-reviewed citations from IFAR and Otolaryngology-HNS, prospective trial data, and registry outcomes — not glossy marketing claims. Display the journal references, n-values, and follow-up windows; rhinologists will check. Hands-on or simulator zone: where the product category supports it, a hands-on station with cadaveric tissue or an endoscopic sinus surgery simulator outperforms any printed material. Rhinologists assess fit by feel and by ergonomics, and a 90-second hands-on encounter often closes faster than a 30-minute presentation.

Static graphics should answer the four questions every rhinologist asks within 30 seconds of approaching the booth: What is the clinical evidence (and how recent is it)? Which surgeons in my network are using this? What is the complication and revision profile? How does this fit into an endoscopic workflow with image guidance, biologic co-management, and in-office sinus procedure capability? Generic "improves patient outcomes" claims signal that you do not know the specialty. Specific outcomes data — by procedure type, by polyp grade, by Lund-Mackay score, by named trial — signals that you do. Our medical conference booth design playbook covers zone layouts and signage hierarchy in more depth.

On-Site Tactics: Symposia, Cadaver Labs, and Surgeon-Level Sales

The vendors who win ARS treat the meeting as a clinical education event with embedded sales activity, not the other way around. Rhinologists come to learn, exchange data, and refine technique. Companies that contribute to that mission — through sponsored symposia, hands-on cadaver labs, journal-quality content, or fellowship-aligned educational support — earn floor traffic and long-term relationships. Companies that show up with consumer-grade marketing get politely walked past.

Sponsored symposia and hands-on cadaver labs are the highest-leverage on-site tactics. A well-designed 60-minute symposium with two or three respected ARS-aligned faculty, followed by a structured cadaveric or simulator lab immediately after, will fill your post-show pipeline more reliably than any other on-site tactic. The cost is meaningful — five-figure faculty honoraria, cadaver lab logistics, and ARS sponsorship fees — but the conversion ratio of attended-symposium to evaluated-product is unusually high in rhinology because hands-on practice is central to surgical adoption.

Structure your surgeon-level sales conversations with care. A rhinologist evaluating a new image-guided navigation platform, a sinus stent, or a CRSwNP biologic referral pathway is making a multi-year clinical and capital decision that affects their OR block, their in-office procedure mix, and their patient outcomes. They do not want a badge scan and a generic drip. They want a structured 20-30 minute conversation with your clinical specialist (not your sales rep), ideally alongside a peer reference call with a similar-volume rhinologist already using the product. Block calendar slots in advance for these conversations and protect them aggressively from interruption.

For walk-up leads, use a tiered approach. Tier 1: target-list rhinologists and division chiefs you have been pursuing — same-day calendar invites for either an in-LA dinner or a clinical specialist call within five business days. Tier 2: high-volume rhinologists not previously on your list — structured nurture sequence with clinical content. Tier 3: fellows, advanced practice providers, and residents — long-cycle nurture aimed at the three-to-five-year horizon when they enter independent practice and make first-time preference-item decisions.

Stacking ARS and AAO-HNSF in LA: A Single October Program

The 2026 calendar puts the ARS 72nd Annual Meeting on October 15-17 and the AAO-HNSF Annual Meeting & OTO EXPO on October 17-20 in the same city — Los Angeles. Most rhinology-focused device vendors should treat this as a single eight-day Los Angeles program, not two separate exhibits. The travel, freight, and staffing math favors a combined plan; the relationship math favors it even more, because the same rhinologists you meet at ARS will see you on the AAO-HNSF floor 48 hours later and form a much stronger impression than they would from either exhibit alone.

Plan the LA program around two distinct audiences. ARS is the deep-specialty audience — rhinologists, skull base surgeons, fellowship faculty, ARS-aligned researchers. AAO-HNSF is the broad ENT audience including otology, laryngology, head and neck oncology, facial plastics, pediatric ENT, and hospital-based ENT department leadership. Your booth, content, and rep mix should shift between the two: clinical specialists and rhinology-focused medical affairs at ARS, broader sales and product marketing at AAO-HNSF, with shared evening events and dinner programs that bring high-priority rhinologists together across both meetings. Our conference-stacking pattern from orthopedics translates almost directly to the ARS-plus-AAO-HNSF play in LA.

Post-ARS Follow-Up: Converting a Q4 Capital and Biologic Cycle

Rhinology device deals close on two distinct timelines that often run in parallel. Surgeon preference items — instruments, sinus stents, in-office sinus procedure devices, simple disposables — can convert in 30-90 days once a high-volume rhinologist decides to switch. Hospital and ambulatory surgery center capital equipment — image-guided navigation platforms, integrated endoscopy stacks, surgical microscope and OR additions — runs 6-18 months through a value analysis committee and the system's capital budget cycle. Biologic and drug-delivery referral pathways for chronic rhinosinusitis with nasal polyps run a third clock: clinical pathway redesign, payer coverage validation, and joint allergy-rhinology workflow alignment over 3-9 months. Post-ARS follow-up needs to run all three clocks without confusing them.

The most common post-ARS mistake is treating every lead as a single timeline. A high-volume rhinologist who tells your team they want to evaluate your sinus stent in Q1 needs daily-cadence follow-up in the first two weeks, an in-OR observation visit booked within 30 days, and a contract draft moving inside 60 days. A capital-equipment lead from a hospital division chief needs immediate scheduling with the value analysis committee, an economic model tailored to the system's payer mix, and a 9-12 month cadence aligned with the system's budget cycle. Our post-conference follow-up playbook covers the segmentation, CRM workflow, and cadence rules that hold up across all three rhinology buyer types.

Build a fellowship-aware nurture track separately from your rhinologist-level pipeline. Today's second-year rhinology fellow is the surgeon making first-time device-preference decisions in 2028 and 2029. Programs that build relationships with fellows at ARS — sponsored fellowship-focused content, hands-on cadaver lab access, and post-show educational support — compound their ARS investment for years. Most vendors ignore fellows entirely. The ones who do not own the next decade of preference decisions in this specialty.

Common Mistakes Vendors Make at ARS

Generic ENT messaging. ARS is not AAO-HNSF. Booth design, faculty selection, and clinical messaging built for a broad otolaryngology audience fall flat with rhinologists. The clinical specificity required is dramatically higher, and the gap is immediately obvious to anyone reading the booth.

Ignoring allergists and the CRSwNP referral pathway. Allergists are increasingly central to chronic rhinosinusitis with nasal polyps care pathways, and many surgical referrals originate from allergist evaluation and biologic management. Booths that talk only to surgeons miss the allergy and joint-management layer that shapes referral patterns. Build a parallel content and conversation track for allergists if your product touches CRSwNP, biologics, or in-office sinus procedures.

Underinvesting in clinical evidence. ARS attendees will read your data, cite it back to you, and call out gaps publicly. Booths that lean on glossy marketing without a current, peer-reviewed evidence base get dismissed quickly. If your evidence base is thin, address that gap honestly and articulate the trial program you are running to close it. Specificity and honesty win this floor.

Sending the wrong rep mix. ARS rewards clinical specialists, medical affairs presence, and senior surgical sales reps over generalist territory reps. If your A-team is on a different show that week, your ARS investment will underperform. For a tightly defined specialty meeting, booth staff is more determinative of outcomes than booth size.

Treating ARS as a one-time investment. Vendors who exhibit at one ARS meeting and disappear earn less than a third of the relationship value of vendors who show up to COSM, Summer Sinus, and the annual meeting consistently. Rhinology is a relationship specialty, and meaningful pipeline compounds over multi-year, multi-meeting presence.

Should You Exhibit at ARS in 2026?

Yes, if you sell into rhinology, endoscopic sinus surgery, in-office sinus procedures, image-guided navigation, sinus implants, endoscopic skull base instrumentation, CSF leak repair, or biologics for chronic rhinosinusitis with nasal polyps. The categories that consistently see strong ARS ROI include endoscopic sinus surgery instruments, balloon sinus dilation systems, image-guided navigation, sinus implants and drug-eluting stents, biologics for CRSwNP (with appropriate joint promotion to allergy), endoscopic skull base instruments, CSF leak repair products, sinus packing and stent materials, in-office sinus procedure devices, allergy diagnostics and immunotherapy products with a rhinology co-promotion angle, and surgical training simulators for endoscopic sinus and skull base procedures. Pair ARS with a focused conference marketing ROI framework and the math usually clears even for first-time exhibitors — if pre-show meeting booking and post-show follow-up discipline is real.

No, if your ENT audience is dominated by otology, laryngology, head and neck oncology, facial plastics, sleep, or pediatric ENT. AAO-HNSF is the better-fit primary meeting, and your rhinology spend should be limited to a tactical presence at the ARS annual in LA only. Similarly, ARS is not the right venue for consumer-direct nasal or sinus wellness products without a specific clinical positioning, peer-reviewed evidence base, and a credible surgeon-facing use case.

If you sell across the broader ENT device ecosystem, the 2026 LA stack — ARS October 15-17 followed by AAO-HNSF October 17-20 — is the highest-leverage single-trip ENT investment of the year. Plan it as one program, staff it as one program, and measure it as one program. Our medical device marketing work with ENT-adjacent device companies consistently shows that the vendors who treat the LA October week as a single integrated effort finish Q4 with materially stronger pipeline than those who exhibit at one or the other in isolation.